Nov 30, 2020 04:08PM
Nov 30, 2020 04:05PM
Nov 16, 2020 08:00AM
Nov 16, 2020 08:00AM
Nov 5, 2020 04:01PM
Nov 5, 2020 04:01PM
Oct 22, 2020 04:14PM Retrophin (RTRX) to Acquire Orphan Technologies
Oct 22, 2020 04:01PM
Oct 22, 2020 04:01PM
Oct 9, 2020 04:01PM
Oct 9, 2020 04:01PM
Sep 21, 2020 08:10AM
Sep 21, 2020 08:00AM
Sep 21, 2020 08:00AM Retrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
Jun 9, 2020 09:23AM
Jun 8, 2020 05:06PM
May 11, 2020 04:01PM
May 11, 2020 04:01PM
Mar 9, 2020 08:06AM
Mar 9, 2020 08:00AM
Mar 9, 2020 08:00AM Retrophin Announces Enrollment of First 190 Patients in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
Oct 11, 2019 04:05PM
Oct 11, 2019 04:05PM
Aug 6, 2019 05:23PM
Aug 6, 2019 04:01PM
Aug 6, 2019 04:01PM
Jul 1, 2019 09:34AM
Jun 28, 2019 04:34PM Retrophin Announces FDA Approval of THIOLA® EC (tiopronin) 100mg and 300mg Tablets for the Treatment of Cystinuria
Jun 28, 2019 04:34PM
May 7, 2019 04:01PM
May 7, 2019 04:01PM
Feb 26, 2019 04:01PM
Feb 26, 2019 04:01PM
Jan 7, 2019 07:20AM
Jan 7, 2019 07:00AM Retrophin Provides Corporate Update and 2019 Outlook
Jan 7, 2019 07:00AM
Dec 27, 2018 08:04AM
Dec 27, 2018 08:00AM
Dec 27, 2018 08:00AM
Dec 20, 2018 08:03AM
Dec 20, 2018 08:00AM
Dec 20, 2018 08:00AM Retrophin Completes Enrollment of Pivotal Phase 3 FORT Study of Fosmetpantotenate in PKAN
Nov 12, 2018 07:02AM
Nov 12, 2018 07:00AM
Nov 12, 2018 07:00AM
Nov 1, 2018 04:01PM
Nov 1, 2018 04:01PM
Oct 29, 2018 05:44AM
Oct 26, 2018 09:18PM Retrophin Reports Positive Long-Term Data from Open-Label Extension of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis
Oct 26, 2018 09:18PM

322,515 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All